Fig. 1From: Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trialFlowchart of participants with overweight/obesity and NAFLDBack to article page